Results 41 to 50 of about 102,854 (205)

Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma

World Journal of Surgical Oncology, 2021
Objective The aim of this study was to evaluate the predictive factors of central lymph node metastasis (CLNM) and BRAF V600E mutation in Chinese patients with papillary thyroid carcinoma (PTC).
Sheng Li Zhou, Yan Ping Guo, Lei Zhang, Tao Deng, Zi Guang Xu, Chao Ding, Wen Cong Sun, Yue Wu Zhao, Ling Fei Kong   +8 more
doaj   +1 more source

RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. [PDF]

, 2013
ObjectiveTo determine the impact of RAS mutation status on survival and patterns of recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) after preoperative modern chemotherapy.BackgroundRAS mutation has been reported ...
Aloia, Thomas A, Andreou, Andreas, Chen, Su S, Curley, Steven A, Kopetz, Scott E, Maru, Dipen M, Shindoh, Junichi, Vauthey, Jean-Nicolas, Zimmitti, Giuseppe   +8 more
core   +1 more source

BRAF mutations in non-Hodgkin's lymphoma [PDF]

British Journal of Cancer, 2003
Ras proteins control signalling pathways that are key regulators of several aspects of normal cell growth and malignant transformation. BRAF, which encodes an RAF family member in the downstream pathway of RAS, is somatically mutated in a number of human cancers. The activating mutation of BRAF is known to play a role in tumour development.
Lee, J W, Yoo, N J, Soung, Y H, Kim, H S, Park, W S, Kim, S Y, Lee, J H, Park, J Y, Cho, Y G, Kim, C J, Ko, Y H, Kim, S H, Nam, S W, Lee, J Y, Lee, S H   +14 more
openaire   +2 more sources

The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma [PDF]

, 2015
The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups.
A Likhacheva, A Snyder, Adam Bloomfield, AM Broadbent, Andrew Furness, Anna Wilkins, C Nieder, C Nieder, D Mathieu, D Rades, E Weltman, FE Harrell Jr, GV Long, J Larkin, J Lorenzoni, J Raizer, James Larkin, JG Lorenzoni, K Margolin, Kevin Harrington, LE Gaspar, M Staudt, MA Hofmann, Nuria Porta, P Royston, PC Tumeh, PW Sperduto, PW Sperduto, R Dummer, R Fisher, R Partl, Richard W Corbett, SL Morris, Stephen Morris, T Serizawa, TK Eigentler, Zohra Ali   +36 more
core   +2 more sources

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience

Therapeutic Advances in Respiratory Disease, 2018
Mutations in the BRAF oncogene are found in 2–4% of all non-small cell lung cancer (NSCLC) patients. The most common activating mutation present within the BRAF oncogene is associated with valine substitution for glutamate at position 600 (V600E) within ...
Arjun Khunger, Monica Khunger, Vamsidhar Velcheti   +2 more
doaj   +1 more source

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers

Frontiers in Oncology, 2018
KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tumor-driven genes. Patients with KRAS/NRAS/BRAF mutations are resistant to anti-EGFR monoclonal antibody therapy.
Qiwei Yang, Sibo Huo, Yujie Sui, Zhenwu Du, Zhenwu Du, Haiyue Zhao, Yu Liu, Wei Li, Xin Wan, Tongjun Liu, Guizhen Zhang, Guizhen Zhang   +11 more
doaj   +1 more source

Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma

Brazilian Journal of Otorhinolaryngology, 2022
Introduction: Papillary thyroid carcinoma is the most frequent endocrine neoplasia and its incidence has tripled over the past 35 years. Although papillary thyroid carcinoma carries a good prognosis, 10%−30% of patients still develop recurrence and ...
Luis Rene Quiroa Barreno, Julia Bette Homem de Mello, Mateus Camargo Barros-Filho, Ana Lucia Francisco, Thiago Celestino Chulam, Clovis Antonio Lopes Pinto, Joao Gonçalves-Filho, Luiz Paulo Kowalski   +7 more
doaj   +1 more source

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab [PDF]

, 2015
Background: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone.
Abouelkhair, KM, Cascinu, S, Del Prete, M, Faloppi, L, Giampieri, R, Ibrahim, EM, Loretelli, C, Mandolesi, A, Maristella, B, Scarpelli, M, Scartozzi, M   +10 more
core   +3 more sources

Detection of BRAF V600E in Fine-Needle Aspiration Samples of Thyroid Nodules by Droplet Digital PCR

International Journal of Endocrinology, 2022
Background. BRAF exon 15 p.V600E (BRAF V600E) mutation has been established as an important molecular marker for papillary thyroid carcinoma diagnosis by ultrasound-guided fine-needle aspiration biopsy (FNAB).
Sang-Yu Lu, Ying-Chao Chen, Jia-Lin Feng, Qin-Yi Zhou, Jing Chen, Chen-Fang Zhu, Miao-Miao Guo, Man-Man Zhang, Qian-Yue Zhang, Meng Lu, Liu Yang, Jing Wu, Shuang-Xia Zhao, Huai-Dong Song, Xiao-Ping Ye   +14 more
doaj   +1 more source

Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report

JTO Clinical and Research Reports, 2021
Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with NSCLC with a BRAF V600E mutation.
Po-Lan Su, MD, Chien-Yu Lin, MD, Yi-Lin Chen, MS, Wan-Li Chen, MS, Chien-Chung Lin, MD, PhD, Wu-Chou Su, MD   +5 more
doaj   +1 more source